Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Orgovyx is a novel oral hormone therapy for prostate cancer

By Brian Buntz | July 21, 2021

Orgovyx Myovant SciencesOrgovyx from Myovant Sciences is a gonadotropin-releasing hormone receptor antagonist that is FDA indicated to treat adults with advanced prostate cancer.

FDA approved the drug in December 2020. In a press release, Richard Pazdur, FDA’s acting director of the Office of Oncologic Diseases, noted that ORGOVYX is “the first oral drug in this class and it may eliminate some patients’ need to visit the clinic for treatments that require administration by a health care provider.”

Pazdur went on to point out that the oral therapy could reduce risk during the COVID-19 pandemic.

 

 


Filed Under: Oncology
Tagged With: advanced prostate cancer, gonadotropin-releasing hormone receptor antagonist, Myovant Sciences, Orgovyx
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

AstraZeneca/Daiichi-Sankyo
FDA approves Enhertu for HER2-low breast cancer
ChemoCentryx/Amgen
Amgen to pay almost $4B for ChemoCentryx
Olema Oncology
Olema Oncology’s OP-1250 could be a game-changing breast cancer drug
Merck in the Drug Discovery & Development Pharma 50
Merck halts Phase 3 Lynparza for futility

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50